EGTX — Egetis Therapeutics AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK2.11bn
- SEK1.97bn
- SEK62.40m
Brief: Egetis Therapeutics Carries Out Directed Share Issue
Brief: Egetis Therapeutics H1 Adjusted EPS SEK -0.4
Brief: Egetis: FDA Awards Tiratricol Breakthrough Therapy Designation In July 2025
Europe Research Roundup: Airbus, BBVA, Domino's Pizza
Brief: Egetis Receives FDA Breakthrough Therapy Designation For Tiratricol
Brief: Egetis Therapeutics Announces Distribution Agreement With Er-Kim
Brief: Egetis Q1 Sales Revenue SEK 12.7 Mln
Brief: Egetis Therapeutics Q1 Adjusted EPS SEK -0.2
Brief: Egetis Therapeutics FY Adjusted EPS SEK -1.1
Brief: Egetis' Emcitate Approved As Treatment For Mct8 Deficiency
Brief: Egetis Gets Positive CHMP Opinion For Emcitate For MCT8 Deficiency Treatment
Brief: Egetis Decides To Explore RTH-Beta As Next Indication For Tiratricol (Emcitate)
Brief: Egetis Therapeutics 9M Adjusted EPS SEK -0.8
Brief: Egetis Therapeutics Carries Out Directed Share Issuances Worth SEK 300 Mln
Brief: Egetis Submits Patent Application To US Patent And Trademark Office
Brief: Egetis Therapeutics H1 Adjusted EPS SEK -0.5
Brief: Egetis Submits Responses To European Medicines Agency's Day 120 List Of Questions
Brief: Egetis - European Thyroid Association Recommends Tiratricol (Emcitate) In New Guidelines
Primary Endpoints